Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00408-X/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=276355044&_hsenc=p2ANqtz-9DGB01t4tU3brSyZx73nHPs6FhZ5cm75HM0B7Sodq9wZN1QS7tAlwWAv7E_Z6Bdf9HAd_EUiW6Hyfn6UQd5Ta8_I4pZw&utm_content=276317812&utm_source=hs_email